ANKRD1 and familial dilated cardiomyopathy: Both Ankrd1+/+ (WT) and Ankrd1−/− (KO) mice were immunized with cardiac α-MHC peptide and EAM/DCM progression was evaluated as shown in Figure 1A. Echocardiographic evaluation of LV chamber dimensions and systolic heart function were performed on 0, 21, 40 days pi and the EAM-induced DCM stage 65 days pi (Figure 1B–E; Figure S3, Table S4, Supplementary Materials).